No Detail Found!

Sofosbuvir Ribavirin Combination Therapy Response in Chronic HCV Patients in Khyber Pakhtunkhwa.

Author(s)
Jehanzeb Afridi Department of Biotechnology, Peshawar Medical College, Peshawar, Khyber Pakhtunkhwa, Pakistan
Nourin Mahmood Department of Biotechnology, Abdul Wali Khan University Mardan, Khyber Pakhtunkhwa, Pakistan
Sajid Ali Department of Biotechnology, Abdul Wali Khan University Mardan, Khyber Pakhtunkhwa, Pakistan
Bashir Ahmad Department of Biotechnology and Microbiology, University of Peshawar, Khyber pakhtunkhwa, Pakistan
Fazal Jalil Department of Biotechnology, Abdul Wali Khan University Mardan, Khyber Pakhtunkhwa, Pakistan
Rahem Sher Department of Biotechnology, Abdul Wali Khan University Mardan, Khyber Pakhtunkhwa, Pakistan
Abstract
Objectives: To see the Sofosbuvir Ribavirin combination therapy response in chronic HCV patients. Material and Methods: This study was conducted in private setup of Hepatitis clinics in collaboration with a private clinical laboratory of Peshawar,Pakistan. The patients were enrolled from July 2016 to December 2017.A total of 65 patients (54 naïve and 11 non- responder/relapser) were enrolled in this study. Age range was 18- 70 years while mean age was 36 ± 2 years. For all of the subjects' biochemical profile and PCR tests were done at the start and end of therapy. All patients were given Direct acting antiviral drugs (DAA) drug for six months and after six month of therapy end of treatment response (ETR) was noted. Results: All the enrolled patients achieved 100% ETR. Alanine amino transferase (ALT) level improved in most of the patients (81%) while there was reduction in Hemoglobin level in 46.5% of the patients. Conclusions: Response rate in the current study is much higher as compared to previous studies conducted on Interferon based ribavairin therapy.
Publication Details
Page(s) 246-249
DOI DOI not available
Published Journal: Journal of Medical Science, Volume: 26, Issue: 3, Year: 2018

Request the full text from PASTIC

References
HajarizadehB,GrebelyJ,DoreGJ, 2013.Epidemiology and natural history of HCV infection,Nature Reviews Gastroenterology and Hepatology 10 553 -8
ZeremskiM,DimovaRB,PillardyJ,de JongYP,JacobsonIM,TalalAH, 2016.Fibrosis progression in patients with chronic hepatitis C virus infection,J Infect Dis 214 1164 -70
VescovoT,RefoloG,VitaglianoG,FimiaGM,PiacentiniM., 2016.Molecular mechanisms of hepatitis C virus-induced hepatocellular carcinoma,Clinical Microbiology and Infection 22 853 -61
HepatitisC,Infection Dammacco F , Sansonno,D, 2013.Therapy for hepatitis C virus-related cryoglobulinemic vasculitis,N Eng J of Med 369 1035 -45
CacoubP,SaadounD,LimalN,SeneD,LidoveO,PietteJC, 2005.PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis,Arthritis & Rheumatism 52 911 -5
MazzaroC,MontiG,SaccardoF,ZignegoAL,FerriC,De Vita S, .Efficacy and safety of peginterferon alfa-2b plus ribavirin for HCV-positive mixed cryoglobulinemia: a multicentre open-label study, -
2011.,Clinical and Experimental Rheumatology 2 933 -6
ZhangJ,NguyenD,HuKQ, 2016.Chronic hepatitis C virus infection: a review of current direct-acting antiviral treatment strategies,N Am J of Med Sci 9 47 -55
GaneEJ,StedmanCA,HylandRH,DingX,SvarovskaiaE,SymondsWT, 2013.Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C,N Eng J Med 368 34 -44
LawitzE,MangiaA,WylesD,Rodriguez-TorresM,HassaneinT,GordonSC, 2013.Sofosbuvir for previously untreated chronic hepatitis C infection,N Eng J Med 368 1878 -87
PolS,SulkowskiM,HassaneinT,GaneE,LiyunN,HoH, 2014.Successful retreatment with Sofosbuvir of HCV Genotype-1 infected patients who failed prior theraphy with PEG-Interferon+ Ribavarin plus 1 or 2 additional DAA's,J Hepatology 60 S23 -5
MangiaA,PiazzollaV, 2014.Overall efficacy and safety results of sofosbuvir-based therapies in Phase II and III studies,Digestive and Liver Disease 46 S179 -85
AhmadB,AliS,AliI,MahmoodN,BashirS,NawazS., 2013.Conventional interferon therapy response among chronic HCV patients in Khyber Pakhtunkhwa,Journal of Infectious Diseases and Therapy 1 -3
AliS,AhmadB,AliI,MahmoodN,AnwarN,SaeediI, 2016.Virological response to conventional interferon therapy combined with ribavirin against various HCV genotypes in Khyber Pakhtunkhwa, Pakistan,Asian Pacific Journal of Cancer Prevention 17 2407 -10
GragnaniL,VisentiniM,FognaniE,UrraroT,De SantisA,PetracciaL, 2016.Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia,Hepatology 64 1473 -82
DammaccoF,TucciFA,LaulettaG,GattiP,De ReV,ConteducaV, 2010.Pegylated interferon-α, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study,Blood 2009 -14
SaadounD,RigonMR,PolS,ThibaultV,BlancF,PialouxG,AliA,AbbasiAS,ShaikhJI, 2017.Demographic features of HCV in Pakistani population,J Med Sci 25 252 -7
HaiderI,HumayunM., 2017.The global burden of HCV,J Med Sci 25 281 -2
0

Citations

0

Downloads

24

Views